Drug alert: 2921 out of 89729 samples declared as NSQ in 2022-23

Drug Alert: Out of this, 2,921 drugs were flagged as "not of standard quality," while 422 were identified as spurious.

December 20, 2023

199

Table of Contents

Last Updated on October 2, 2024 by The Health Master

Drug alert

Drug alert: In a recent revelation in the Rajya Sabha, Minister of State for Health Bharati Pravin Pawar shared concerning data regarding the quality of drugs tested between April 2022 and March 2023.

This article delves into the statistics, legal actions taken, exclusions, and regulatory measures in place to ensure the safety and efficacy of pharmaceuticals.

Follow us on WhtasApp Channel

A Glimpse into the Numbers

Between April 2022 and March 2023, a staggering 89,729 drug samples underwent rigorous testing.

Drug Alert: Out of this, 2,921 drugs were flagged as “not of standard quality,” while 422 were identified as spurious.

These figures raise questions about the robustness of the drug manufacturing and distribution system.

Legal Ramifications

Minister Pawar disclosed that 642 prosecutions were initiated against those involved in the manufacturing, sale, and distribution of spurious or adulterated drugs.

Simultaneously, 262 individuals faced arrest during this period, highlighting the severity of the issue at hand.

Click for Guidance documents for industry

Exclusion of Rajasthan Data

It’s crucial to note that the provided data excludes information from Rajasthan, leaving a gap in our understanding of the nationwide scenario.

The absence of this data prompts further inquiries into the reasons behind the exclusion and its potential impact on the overall statistics.

Comparative Analysis

To gauge the magnitude of the issue, a comparison with the previous year’s data is essential.

Between April 2021 and March 2022, 88,844 samples were tested, revealing 2,545 drugs as not meeting standard quality and 379 as spurious.

The uptick in numbers in the current year raises concerns about the trajectory of drug quality in the country.

Click for more articles on CDSCO

Regulatory Compliance Assessments

Addressing concerns, Minister Pawar highlighted the role of the Central Drugs Standard Control Organization (CDSCO) and State Drugs Controllers (SDCs) in conducting risk-based inspections.

A total of 261 premises were scrutinized based on criteria such as product criticality, complaints, and drugs declared as not meeting standards.

Actions Taken Based on Inspections

The inspections led to over 200 regulatory actions, including the issuance of show cause notices, stop production orders, and suspension or cancellation of licenses and product licenses.

These stringent measures underscore the commitment to upholding drug quality standards.

Minister’s Statement

Minister Pawar emphasized the importance of regulatory measures in maintaining the integrity of drug manufacturing premises in the country.

The findings underscore the need for continuous assessment and stringent actions to curb the proliferation of substandard and spurious drugs.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

Click for Guidance documents for industry